What this pack is
Invokana is the brand name in this record; canagliflozin is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
InvokanaGeneric namecanagliflozin
How this medicine works
The FDA/U.S. DailyMed label describes canagliflozin as an SGLT2 inhibitor. SGLT2 in the kidney's proximal tubules participates in reabsorbing most filtered glucose; canagliflozin inhibits SGLT2, reducing that reabsorption, lowering the renal glucose threshold and increasing urinary glucose excretion. This explains a pharmacological pathway, not an individual's glucose, kidney function, suitability, fluid intake, dose, combination or switching plan.
Read source: United States ↗Current regulatory record · reviewed 2026-08-28More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Invokana
- Generic name
- canagliflozin
- Dosage-form class
- INVOKANA canagliflozin film-coated oral tablets: 100 mg and 300 mg. Current-label text identities are retained for 30-count bottles, while exact current official display panels are retained for 90-count bottles. See the primary label for 500-count and other packages.
- Route
- Route documented in the linked source label
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (revised Jun 2026)
Canagliflozin 100 mg per tablet; 30-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 50458-140-30
- Form and route
- INVOKANA canagliflozin film-coated oral tablet · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-26; actual marketing, stock and availability are not established.
- canagliflozin
- 100 mglabelled amount per tablet; not an individual's tablet count, frequency, missed-use instruction or conversion
- Package
- 30 tablets per bottle
- Labelled appearance
- yellow · capsule-shaped film-coated tablet · imprint CFZ / 100
United States label · Current U.S. DailyMed public label (revised Jun 2026)
Canagliflozin 300 mg per tablet; 30-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 50458-141-30
- Form and route
- INVOKANA canagliflozin film-coated oral tablet · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-26; actual marketing, stock and availability are not established.
- canagliflozin
- 300 mglabelled amount per tablet; not an individual's tablet count, frequency, missed-use instruction or conversion
- Package
- 30 tablets per bottle
- Labelled appearance
- white · capsule-shaped film-coated tablet · imprint CFZ / 300
United States label · Current U.S. DailyMed public label (revised Jun 2026; reviewed 28 Aug 2026)
Canagliflozin 100 mg per tablet; 90-tablet bottle (NDC 50458-140-90)
- Product code
- NDC 50458-140-90
- Form and route
- INVOKANA canagliflozin film-coated oral tablet · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- canagliflozin
- 100 mglabelled amount per tablet; not an individual's tablet count, frequency, missed-use instruction or conversion
- Package
- 90 tablets per bottle
- Labelled appearance
- yellow · capsule-shaped film-coated tablet · imprint CFZ / 100
United States label · Current U.S. DailyMed public label (revised Jun 2026; reviewed 28 Aug 2026)
Canagliflozin 300 mg per tablet; 90-tablet bottle (NDC 50458-141-90)
- Product code
- NDC 50458-141-90
- Form and route
- INVOKANA canagliflozin film-coated oral tablet · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- canagliflozin
- 300 mglabelled amount per tablet; not an individual's tablet count, frequency, missed-use instruction or conversion
- Package
- 90 tablets per bottle
- Labelled appearance
- white · capsule-shaped film-coated tablet · imprint CFZ / 300
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
INVOKANA label reading: match 100/300 mg and 30/90-count packs item by item
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the current U.S. DailyMed label to check INVOKANA, canagliflozin, oral tablets, 100 mg or 300 mg per tablet, NDC, 30-count text identities and exact 90-count display panels. These numbers are product-identity fields; the page does not turn them into an individual's tablet count, timing, missed-use action or switching conclusion.
- 100 mg and 300 mg are different tablet strengths. Colour, imprint and bottle count only help compare the cited U.S. label. They do not mean a person can split, combine, double, halve or substitute another canagliflozin or glucose-lowering product by milligrams.
- Label terms such as diabetes, cardiovascular and kidney do not enable a webpage to decide personal suitability. Kidney function, volume status, age, the complete medicine list, history and the current prescription need professional review together.
- INVOKAMET, INVOKAMET XR and another metformin-containing combination cannot be treated as the same medicine because of a name or shared ingredient. Any actual co-use question involving insulin, an insulin secretagogue, a diuretic or another glucose-lowering medicine requires review of the complete medicine list by a pharmacist or prescribing team.
- Adverse-reaction and warning material in a label is safety information to read and review, not a webpage rule that decides continuation, pausing, switching or self-management for anyone. With an acute or serious concern, use timely local medical or emergency support.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-28
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. INVOKANA canagliflozin public label (Janssen; revised Jun 2026) ↗Current regulatory record · reviewed 2026-08-28
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-28FDA: INVOKANA canagliflozin U.S. prescribing information (NDA 204042; revised Jun 2026) ↗Current regulatory record · reviewed 2026-08-28
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Invokana (canagliflozin). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Invokana is the brand in this record and canagliflozin is the active-ingredient name. Check both with the dosage form (INVOKANA canagliflozin film-coated oral tablets: 100 mg and 300 mg. Current-label text identities are retained for 30-count bottles, while exact current official display panels are retained for 90-count bottles. See the primary label for 500-count and other packages.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. INVOKANA canagliflozin public label (Janssen; revised Jun 2026) ↗Current regulatory record · reviewed 2026-08-28
- FDA: INVOKANA canagliflozin U.S. prescribing information (NDA 204042; revised Jun 2026) ↗Current regulatory record · reviewed 2026-08-28
HOW IT WORKS · NOT A TREATMENT PLAN
How canagliflozin works: it reduces the kidney's reabsorption of filtered glucose
- “More glucose leaves in urine” cannot turn one urine-glucose result, glucose reading, thirst, urine-volume change or weight change into a decision to self-adjust, make up or stop medicine. Actual readings and symptoms need the exact product, complete medicine list and professional assessment.
- Sharing the SGLT2 class does not make INVOKANA, JARDIANCE, FARXIGA or another product self-combinable, alternatable or substitutable; a shared mechanism instead signals the need to review the complete medicine list, not a personal combination answer.
- Mechanism cannot decide next steps for diabetes, foot concerns, infection, dizziness, vomiting, abdominal pain, breathing trouble or a perioperative situation. With an acute, serious or concerning symptom, use local medical support rather than change medicine from a mechanism page.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: INVOKANA canagliflozin U.S. prescribing information (NDA 204042; revised Jun 2026) ↗Current regulatory record · reviewed 2026-08-28
- DailyMed (NLM): current U.S. INVOKANA canagliflozin public label (Janssen; revised Jun 2026) ↗Current regulatory record · reviewed 2026-08-28
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Invokanacanagliflozin
This page includes an exact current U.S. public-label package panel for Invokana, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the FDA label
The FDA label archive linked here lists Initial U.S. Approval: 2013. This historical locator is not a conclusion about current approval, availability, holder or another market.
FDA: INVOKANA prescribing information ↗FDA label archive version
This page links the 2026-06 FDA label archive as a traceable reading entry point. Current labeling, strength, indication and safety information require separate verification against the target market’s current document.
FDA: INVOKANA prescribing information ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.